^
    8d
    BGB-21447-101: A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies (clinicaltrials.gov)
    P1, N=112, Active, not recruiting, BeiGene | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    BGB-21447
    2ms
    BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer (clinicaltrials.gov)
    P1, N=120, Recruiting, BeiGene | N=92 --> 120
    Enrollment change
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    fulvestrant • BGB-21447
    7ms
    A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies (clinicaltrials.gov)
    P1, N=112, Recruiting, BeiGene | N=85 --> 112 | Trial completion date: Oct 2026 --> Apr 2027 | Trial primary completion date: Mar 2026 --> Apr 2027
    Enrollment change • Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    BGB-21447
    10ms
    BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer (clinicaltrials.gov)
    P1, N=92, Recruiting, BeiGene | Not yet recruiting --> Recruiting
    Enrollment open
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    fulvestrant • BGB-21447
    11ms
    BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer (clinicaltrials.gov)
    P1, N=92, Not yet recruiting, BeiGene
    New P1 trial
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    fulvestrant • BGB-21447
    over1year
    A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies (clinicaltrials.gov)
    P1, N=85, Recruiting, BeiGene
    Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    MYC translocation
    |
    BGB-21447
    over2years
    Phase 1 Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies (clinicaltrials.gov)
    P1, N=66, Recruiting, BeiGene | Not yet recruiting --> Recruiting
    Enrollment open
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    MYC translocation
    |
    BGB-21447
    over2years
    Phase 1 Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies (clinicaltrials.gov)
    P1, N=66, Not yet recruiting, BeiGene
    New P1 trial
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    MYC translocation
    |
    BGB-21447